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This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer
metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging’s (MRI’s)© 2018 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open




2 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH
white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of
other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic
information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and
feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian
cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition
sequences and improved MRI hardware have been developed. It will be important to continue investigation and
development of existing and new probes in animal models. Improved polarization technology, efficient
radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the
technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI
might fill existing needs in current clinical research and practice, and complement existing metabolic imaging
modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important
factors in translating the technology for clinical research in oncology. This white paper is intended to provide
recommendations with this goal in mind.
Neoplasia (2019) 21, 1–16Introduction
Recent advances in cancer metabolism have generated considerable
interest among clinicians.1,2 However, the only imaging agent regularly
used in the clinic to assess metabolism is the glucose analog [18F]
fluorodexoyglucose (FDG), a positron emission tomography (PET) tracer
that reports on local glucose uptake in many cancers, inflammation, and
other processes. While FDG PET has been an extremely successful
approach, it cannot assess downstreammetabolism that is often important
to more fully understand cancer. Hyperpolarized magnetic resonance
imaging (HPMRI) provides a unique window into metabolic alterations
based on its ability to measure molecular transformations of the imaging
agent.3–6 Themethod dramatically, although temporarily, increasesMRI
signal, which allows in vivo imaging of biologically active molecules that
was impossible with conventional methods. Dynamic nuclear polariza-
tion of 13C-labeled biomolecules (probes) is currently the dominant
hyperpolarization process used for preclinical work, and it is the only one
that has been translated to patient studies. Due to space limitations, this
white paper will focus on dynamic nuclear polarization–based
polarization of 13C probes, although there are other methods to generate
HP 13C-probes including para-hydrogen and brute force–based
approaches,5,7–9 and other nuclear magnetic resonance active nuclei
such as 129Xe, 15N, and 31P have been hyperpolarized.10,11
The potential to diagnose and better characterize cancer biology,
predict cancer progression,12–17 and monitor early response to
treatment16,18–33 using HP MRI was highlighted in the first NIH
white paper on this technology in 2011. Since then, a polarizer
capable of producing hyperpolarized material for human injection was
commercially introduced, and the safety of hyperpolarized [1-13C]
pyruvate as a tool for measuring changes in tumor metabolism in
patients was demonstrated.34 This white paper will highlight
preclinical advances, technical needs, and early experience with
patients and discuss how HP MRI might fill existing needs in
current clinical research and practice. Finally, we will examine
obstacles to HP MRI's widespread clinical use and outline a path for
clearing them.The Continuing Need for Animal Models
In addition to providing the only plausiblemethod for testing the feasibility
and safety of new HP molecular probes, preclinical animal studies are
crucial for refining the methods for their use in specific diseases and for
validating quantitative HP measurements of metabolism against tissue
assays. Animal studies also provide the opportunity to better understand
fundamental aspects of biochemistry and its modification by disease,
therapy, nutritional state, and prescribed experimental conditions,
which is possible in preclinical models but not in patients. Even if some
HP probes prove inappropriate for clinical translation, their use in
preclinical studies can still yield information of real clinical value by
elucidating themetabolic pathways that novel treatment strategies could
target.13,35,36 Studies in animal models are also critical to drive basic
science discovery of new metabolic drug interventions, where further
applications of this technology might be beneficial in helping patients.
HPPyruvate for Diagnosis, Progression, and Response to Therapy
[1-13C]pyruvate was among the first HP probes introduced and
remains the most widely studied in preclinical cancer models because
it is easy to polarize, T1 is relatively long, and it occupies a critical
branch point central to a number of significant metabolic pathways.
Pyruvate is the product of glycolysis, and its major fates include
reduction to [1-13C]lactate via the enzyme lactate dehydrogenase
(LDH) or oxidative metabolism to acetyl-coA with production of [13C]
bicarbonate in the mitochondria. Both processes result in an altered
chemical shift that HPMRI is able to image at uniquely high temporal
resolution. Although some exceptions have been observed,37,38 the
majority of preclinical cancer studies using HP pyruvate as a biomarker
have shown increased conversion to HP lactate, consistent with the
elevated lactate production (Warburg effect) that is an established
characteristic of most cancerous cells.12–17,39–42 These studies also
demonstrated a mechanistic link between increased HP lactate signal
and other cancer-associated cellular alterations such as the elevated
expression of LDHA and monocarboxylate transporters, and lowered
pH in the extracellular environment. The accompanying reduction in
Neoplasia Vol. 21, No. 1, 2019 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. 3pyruvate dehydrogenase activity can also be directly measured via
appearance of HP [13C]bicarbonate from [1-13C]pyruvate or HP
[5-13C]glutamate from [2-13C]pyruvate.19,20
Elevated transformation of hyperpolarized pyruvate to lactate has
been established as a predictor of tumor progression in the transgenic
adenocarcinoma of the mouse prostate "model" and genetically
engineered pancreatic cancer models,43,44 while a similar effect was
also seen in longitudinal studies of liver cancer models,45 alongside
increased transamination of pyruvate to alanine. The latter effect
appears to be specific to the hepatic tumor phenotype and may be
diagnostic of tumor type or stage. These applications demonstrate HP
MRI's value as a tool for prognosis and treatment planning. In
addition, the ability to measure the metabolic information at a key
branch point involved in downstream glucose metabolism provides
information that is unique and complementary to FDG PET. HP
[1-13C]pyruvate MRI provides insight into metabolism of a substrate
other than glucose, and the synergistic combination of the two
methods may offer significant advantages in identifying and
characterizing cancer. For example, it was recently demonstrated in
a PET/MRI study where FDG-PET and HP MRI were simulta-
neously acquired (hyperPET) that FDG-PET cannot demonstrate the
Warburg effect per se but does discriminate between glycolysis and
oxidative phosphorylation in contrast to HP MRI.46,47
HP MRI of pyruvate and its products is sensitive to the effects of
anticancer therapies including DNA-damaging agents, radiotherapy,
antivascular agents, targeted therapies, hormonal therapy, and
antimetabolites—all of which have been reported to lead to a drop
in HP lactate labeling, mediated by different mechanisms in the
various treatments.9,11–25 Additionally, the metabolism of HP
fumarate to malate is sensitive to therapies that induce necrosis,
such as VEGF neutralization and chemotherapy.31,33,48 Despite
some exceptions,38,48 in general, preclinical data suggest that
measurements from HP MRI of pyruvate predicts posttherapy cancer
viability and aggressiveness. It will be important to preclinically test
the hypothesis that therapeutic response can be determined at an
earlier stage than that at which reduced tumor size is observable using
anatomic imaging modalities as is done in the Response Evaluation
Criteria in Solid Tumors approach.49 Given the needs of a
personalized approach to treatment, HP MRI's capacity to expedite
assessment of response to therapy holds obvious value; this may be
especially true in the case of early detection of nonresponse to therapy,
which would enable more rapid adoption of alternate treatment
strategies.
Existing and Prospective Probes
Numerous molecules in addition to [1-13C]pyruvate have been
successfully polarized and used to study multiple biological processes,




bonate, [1,4-13C2]fumarate, and several others.
50,51 [1-13C]acetate
has been used to study tricarboxylic acid cycle flux and fatty acid
oxidation in heart and skeletal muscles through its conversion to
acetyl-CoA by acetyl-CoA synthase,52,53 while HP butyrate has been
utilized to study ketone body metabolism and short-chain fatty acid
pathways.54 HP alanine has been employed as an alternate probe to
study metabolism in the muscle and liver.55,56 HP glucose has been
used to monitor flux via the pentose phosphate pathway, as well as
glycolytic flux and lactate production57,58; [1-13C]dehydroxyascor-
bate has been imaged and used to monitor intercellular redox statusand to inform on response to treatment by measuring the modulation
of the tumor microenvironment59–61; HP [1-13C]alpha-ketogluta-
rate has been used to track the neomorphic oncogenic activity of
mutant IDH via its metabolism to the oncometabolite
2-hydroxyglutarate and glutamate.62,63 More recently, HP [1-13C]
glutamine has been used to directly measure metabolic flux to
2-hydroxyglutarate, demonstrating a methodology to trace nutrient of
origin to a product in vivo.64 HP [2-13C]dihydroxyacetone has been
used to assess hepatic gluconeogenesis,65 while HP acetoacetate has
been proposed as an indicator of mitochondrial redox status, although
its utility has not yet been studied in tumors.66 The utility of inert
metabolic probes such as 13C-urea or 13C,15N2-urea has also been
shown in simultaneous acquisitions with metabolized species as a
means to normalize delivered agent concentration and uptake
kinetics, or as independent markers of perfusion in tumor tissue.67
This combined acquisition has the potential to alleviate technical
challenges in accurately determining metabolic and hemodynamic
changes associated with treatment response.68–70
Numerous biologically relevant, potentially polarizable molecules
remain unstudied,71 and new HP probes to detect and assess response
to various types of cancer treatment are urgently needed. For example,
because MRI of HP pyruvate is unable to differentiate increased
lactate production associated with tumor cells from that associated with
inflammatory cells, other probes—such as the recently tested HP
[6-13C]arginine—are necessary for monitoring response to therapies
that target this cell type.72 In addition, the development of
hyperpolarized biomarkers capable of monitoring response to the
most promising immunotherapies currently in use, such as checkpoint
inhibitors, is a major unmet need which should command immediate
preclinical attention. Probes tailored to the innate or designedmetabolic
characteristics of such cellular therapeutic agents would be extremely
valuable for assessing treatment efficacy at a very early stage.
Further Avenues of Preclinical Animal Study
Preclinical animal studies enable investigation of appropriate
methods to report HP data or integrate multiple HP measurements,
for example, through the development and testing of methods for the
true simultaneous measurement of perfusion and metabolism to
improve quantitation69 and facilitate identification of poorly perfused
but metabolically active disease that is often highly aggressive and
difficult to treat.73 The possibility of acquiring such a combined
measurement was demonstrated using copolarized [1-13C]pyruvate and
13C urea in rats: metabolic alterations were registered via the conversion
of pyruvate into 13C bicarbonate, while alterations in perfusion were
measured via changes in myocardial signals of pyruvate and urea.60 The
development of HP probes and pulse sequences capable of simulta-
neously measuring perfusion/metabolism mismatch in cancerous tissue
has the potential to provide valuable information regarding tumor
heterogeneity, with obvious implications for the development of more
sensitive and personal treatment.73 Similar possibilities exist for additional
ratiometric measurements (e.g., local pH derived from CO2:HCO3
ratio,74–78 or redox state in different intracellular compartments derived
from lactate:pyruvate ratio,37,79,80 α-ketoisocaproate:leucine ratio,81,82
or ascorbate:dehydroascorbate ratio).59,60 These combinations are being
explored or developed in animal, organ, and cell research models with the
potential for future clinical application. The unique ability to image
multiple metabolites simultaneously—either through the injection of a
single hyperpolarized agent that is variously metabolized or via the
injection of several HP agents at once—means that HPMRI technology
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ratiometric measurements are potentially subject to bias in the case of
differing uptake or relaxation characteristics, preclinical models are critical
for validation using histological and invasive techniques that are not
practical in human subjects.
In addition to exploring HP technology, preclinical animal studies
enable measurements that are not feasible in human subjects for
reasons such as invasiveness, toxicity, or the current inability to
hyperpolarize substrates in sufficient volume. Studies using geneti-
cally engineered and patient-derived xenograft models enable the
combined use of PET and HP MRI, as well as the collection of a
robust spectrum of supporting in vivo and histological measurements,
including metabolite and enzyme profiles as well as histochemical
measurements of enzyme heterogeneity, which can both confirm and
enhance the data collected via these primary imaging modalities.
While the ability to collect such supplementary measurements is
undoubtedly crucial to validating the accuracy of primary measure-
ments enabled by HP probes, its ultimate value may lie in the more
general expansion of our understanding of the biochemical properties
characteristic of specific disorders. For example, HP probes are
currently being used to assess the progression of lung83 and brain84
injury, yielding valuable insights into the mechanism of injury
propagation. While these studies are not directly applicable to
imaging human injury using HP agents in the clinic, the information
gained will help guide therapeutic approaches that could have
significant clinical impact.
Needs and Future Directions
There is substantial need for preclinical polarizers capable of
achieving high polarization and tailored for producing masses of
material suitable for rodent exams. Such a polarizer that is less
expensive than a clinical device would dramatically expand preclinical
efforts and speed clinical investigations. High levels of polarization
increase the signal-to-noise ratio and potentially open up previously
undetectable biological pathways for study. High levels of polarization
may also allow a reduction in the injected probe concentration. HP
probes are injected at physiologic or supraphysiologic doses, and
preclinical studies investigating the extent to which physiologic
concentrations of HP probe might perturb in vivo metabolism
relative to a tracer approach like PET are key to the proper
interpretation of HP MRI findings. As previous work has
demonstrated, this increased polarization is most easily achieved by
employing higher magnetic fields and lower temperatures during the
polarization process.85,86
Optimized pulse sequences can also be used to preserve the
magnetization of specific hyperpolarized substrates while enhancing
the detection of products.4,87 Since the lack of standardized
techniques remains an obstacle to the growth of HP MRI as a field
of study, this represents a potential opportunity for the research
community to collaborate with small imaging system manufacturers
on the creation of standard imaging sequences and basic processing
protocols, thereby possibly expanding the use of HP MRI techniques
beyond labs with a strong MRI physics focus. Other beneficial
technical improvements would include the development of a less
complex user interface, as well as a more direct, rapid mechanism for
the delivery of polarized agents into the animal or cell or tissue culture
bioreactor.
The development and optimization of new hyperpolarized
molecular probes, and preclinical studies that accurately recapitulateimportant aspects of human disorders—whether using primary cells
and tissues, genetically engineered, patient-derived xenograft, or other
models—continue to be of great value. Robust mechanistic validation
linking hyperpolarized metabolic observations to established biolog-
ical events are also essential to establish the value of hyperpolarized
imaging approaches and their potential limitations. Significant effort
is currently under way—and should be further encouraged—to
explore the use of HP imaging biomarkers to inform on a variety of
disease conditions and therapeutic strategies and to integrate this
unique new information to positively affect outcome. The combined
use of targeted therapeutic approaches and HP MRI in these models
will provide a framework for accessing HP biomarkers of treatment
response for clinical translation. It is also important to conduct more
studies to validate the use of HP MRI in combination with other
imaging modalities such as PET, as was recently done during a single
imaging session in a canine cancer model.46,47 The value of
combining these measurements lies not only in a more complete
characterization of the cancerous tissue being imaged but in reduced
scan time and more efficient use of resources.Necessary Technical and Analytic Developments
Success with preclinical studies encouraged a more translational focus.
In order to enable clinical trials, several specific technical develop-
ments were necessary. In the following section, we will outline some
of the recent technical progress and note additional opportunities.
A Device for Polarization
Over the past 10 years, there have been significant improvements
in polarizer hardware, from initial prototypes suitable for rodent
exams to current commercial products that can support human
studies.88 The performance in terms of polarization and speed of
delivery has been adequate for initial [1-13C]pyruvate studies, but
further developments are needed to achieve higher and faster
polarizations reliably with increased cost-effectiveness, and to
streamline methods of HP probe sterile delivery for pyruvate and
other HP probes for future clinical research. Next-generation
polarizers that are optimized for preclinical research will also be
vital for supporting the development of new hyperpolarized agents
and their use in basic science and translational research.
Imaging Hardware
Another important commercial goal should be improved 13C MR
imaging hardware. While each major MR scanner vendor offers
product hardware enabling the excitation and detection of hyperpo-
larized signals at the 13C frequency, several additional modifications
would significantly improve the performance and applicability of this
technology. Commercially available double-tuned body coils would
greatly benefit human studies by allowing uniform excitation for 13C
over any target disease site, as is the case for conventional 1H MRI.
Current studies have been limited by both the 13C detector hardware
and short acquisition times due to metabolism, signal relaxation, and
excitation losses; thereby necessitating the use of strategies that more
efficiently encode magnetization.69,89,90 As in 1H MRI, detector
arrays with a high number of elements can facilitate higher
acceleration rates to generate images faster and with increased spatial
coverage and resolution. For optimal clinical studies, scanners with a
greater number of receive channels (at least 32 channels) are needed to
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Figure 1. Schematic showing the required components for HP 13C MRI clinical translation. Thirty-two-channel head coil.
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high-quality “standard of care” 1H MRI alongside sensitive 13C
detection without repositioning or replacing coils in order to enhance
patient comfort and workflow. Higher-performance gradients will
also be critical for improving the speed, coverage, and performance of
HP 13C MRI, which requires four times higher gradient strengths to
achieve the same effect as for 1H MRI. The progress seen in highly
parallel acquisition of 1HMRI over the past few years provides reason
to believe that these radiofrequency (RF) coil challenges can be met
within the constraints imposed by currently available gradient bores.
The increased costs would be a very small fraction of total system cost
and easily justified by the greatly enhanced capabilities. The
development of appropriate phantoms that enable testing of new
techniques for HP 13C MRI prior to human studies is also important
for advancing the field. Static phantoms containing 13C-enriched
compounds facilitate technical development and quality assurance
testing to confirm scanner and coil performance at thermal
equilibrium, while dynamic phantoms that simulate the kinetics of
chemical conversion in vivo91 are important to develop and validate
quantitative dynamic imaging measurements.
Acquisition Methods for Human Studies
The high signal-to-noise ratio provided by this hyperpolarization
technique makes high-resolution acquisitions feasible. However,
rapid metabolism and short T1 relaxation times can limit the matrix
size—and thus the spatial resolution and coverage possible—with
conventional phase-encoding. The MR acquisition techniques used
for initial animal studies and the first human trial34 were limited in
spatial coverage (typically b8 cm) and dynamic temporal information.
This clinical trial used single-slice dynamic 13C echo-planarspectroscopic imaging (EPSI) in some patients to estimate the correct
starting time for a 12-second 3D EPSI single time-point acquisition
in subsequent patients with a small FOV of 8-10 cm.34 Dynamic 1D
EPSI measurements efficiently encode frequency and space along the
readout direction following a single excitation. Extension to multiple
spatial dimensions requires additional excitations and phase encoding
repetitions for each dynamic time point. New acquisition and analysis
techniques are needed for volumetric, dynamic HP MR data with
improved spatial coverage and temporal resolution. Most preclinical
and clinical research studies have used spectroscopic-based acquisi-
tions, but imaging-based acquisitions including balanced steady-state
free precession sequences,92,93 spectral-selective echo-planar,94 and
spiral trajectories68,95–97 have clear advantages in terms of speed and
ease of implementation and analysis. Methods combining 13C and
1H excitation and reception could benefit the detection of many
metabolites via decoupling and indirect detection.98,99
Reconstruction, Dynamic Modeling, and Enzyme Rate Con-
stants
Ideal dynamic MRSI data would be resolved in three spatial
dimensions, the spectral dimension, and time with adequate coverage
and speed to enable reliable quantification of metabolic parameters.
Fortunately, the spectrum is sparse, with only a few spectral lines. In
addition, the time dimension is slowly varying. These two features
allow the amount of encoding required to be greatly reduced by using
compressed sensing reconstructions along with low-rank or
model-based reconstruction in the temporal dimension.89,100,101
Spatial data reduction strategies, including parallel and constrained
imaging methods, are crucial for reducing the number of excitations
that are necessary to reconstruct dynamically changing data.102 Fewer
Figure 2. Images are from a representative patient with a current PSA of 3.6 ng/ml, who had biopsy-proven prostate cancer in the left apex
(Gleason grade 3 + 4) and received the highest dose of hyperpolarized [1-13C]pyruvate (0.43 ml/kg). (A) A focus of mild hypointensity can
be seen on the T2-weighted image, which was consistent with the biopsy findings. (B to D) 2D localized dynamic hyperpolarized [1-
13C]
pyruvate and [1-13C]lactate from spectral data that were acquired every 5 seconds from voxels overlapping the contralateral region of
prostate (turquoise), a region of prostate cancer (yellow), and a vessel outside the prostate (green). The dynamic data were fit to provide
kPL as described previously.
139 Figure taken from Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al.
Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate. Science Translational Medicine
2013;5:198ra108-198ra108.
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coverage, higher excitation angles, or prolonged interaction with
target biology. Optimized excitation schemes are required to permit
further sensitivity enhancement.
Parallel imaging reconstructions can be challenging since signal at
thermal equilibrium is too weak for practical measurement of sensitivity
maps. Autocalibrating methods such as GRAPPA (GeneRalized
Autocalibrating Partial Parallel Acquisition) can avoid wasting
polarization and imaging time acquiring sensitivity maps but can be
problematic because the fully sampled central region can be a large
fraction of the sampled k-space volume which limits acceleration. Care
must also be taken to ensure that undersampled parallel imaging data are
acquired in such a way that the data are self-consistent enough to satisfy
fundamental assumptions about the relationship between under-
sampled data. Alternatively, undersampled k-space data can be usedto compute the coil sensitivities as with a calibration-less approach for
HP 13C MR.103 Further investigations are needed to develop
acquisition strategies that minimize uncertainty while maximizing the
efficiency of spatial, temporal, and spectral encoding—including
methods that exploit redundant information that could be derived
from conventional 1H MRI.
MRI of hyperpolarized substrates is unique among diagnostic
imaging modalities in its ability to provide information about
dynamic chemical interactions and imaging agent metabolism. New
approaches for characterizing the transient interaction between the
imaging agent and targeted biological processes are therefore required.
A variety of approaches have been proposed, including semiquanti-
tative area under the curve measurements—such as the normalized
lactate ratio— that reflect the ratio of locally observed product to
precursor and product, “snapshot” measurements of metabolite
AB
Figure 3. Representative axial T2-weighted anatomic image and corresponding water apparent diffusion coefficient (ADC) image and T2W
image with an overlaid pyruvate-to-lactate metabolic flux (kPL) image and corresponding HP
13C spectral array for a 52-year-old prostate
cancer patient with extensive high-grade prostate cancer (A) before therapy and (B) 6 weeks after initiation of androgen ablation and
chemotherapy. Before treatment, the region of prostate cancer can be clearly seen (red arrows) as a reduction in signal on the T2W and
ADC images, and increased HP lactate and associated kPL on. Pretreatment, HP [1-
13C]pyruvate CS-EPSI demonstrated a large region of
high HP Lac/Pyr ratio, resulting in a high kPL, which is consistent with region of decreased T2 MRI signal and water ADC associated with
biopsy-proven Gleason 4 + 5 prostate cancer. At 6 weeks after initiation of androgen deprivation therapy, repeat HP 13C MRI
demonstrated nearly complete abrogation of elevated HP lactate peaks and associated near-complete diminution of intratumoral kPL
values on dynamic imaging (kPL max 0.025 s
−1 at baseline and 0.007 s−1 on follow-up). Notably, there were negligible change in size of
tumor on T2-weighted MRI and only a modest change on ADC imaging, supporting the ability of HP
13C MRI to detect early metabolic
responses before such a response can be ascertained using standard radiographic criteria. Concordant with these findings, the patient
subsequently achieved a marked clinical response, with an undetectable serum PSA nadir at 6 months after ADT initiation. Figure taken
from Aggarwal, R., Vigneron, D.B., and Kurhanewicz, J. Hyperpolarized [1-13C] Pyruvate Magnetic Resonance Imaging Detects an Early
Metabolic Response to Androgen Ablation Therapy in Prostate Cancer, Eur Uro, July 23, 2017;72(6)1028-1029. PMCID:5723206.
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kinetic analysis of dynamic multispectral data has shown the ability
in both preclinical and human studies (Figure 1) to derive rate constants
for substrate conversions such as kPL, the spectroscopic/imaging
biomarker for the calculated rate at which HP pyruvate is converted
into lactate.18,34,69,104,105 Quantitative measures such as kPL can
provide important quantitative parameters for many applications where
precise measurements are needed to quantify changes in specific drivers
of aerobic glycolysis. Recent literature shows the strong correlation
between perfusion and metabolic measures of kPL
69,94 with cancer
aggressiveness and response to therapy. To realize the inherent promise
of the unprecedented new information afforded by HP substrates,
further research is critically needed to develop and test new accurate,
reproducible quantitative analysis methods.
Once achieved, the technical and analytical developments outlined
above should help to significantly accelerate the translation of HP 13C
MRI to the clinic and increase its biomedical value—both by
enabling studies which offer further proof of the improved molecular
imaging capabilities it has already displayed and by optimizing their
potential clinical utility.
Translation to Patients with Cancer
The first-in-human study convincingly demonstrated that injection
of HP [1-13C]pyruvate is safe and that imaging metabolic products ofhyperpolarized [1-13C]pyruvate metabolism is feasible 34. Since then,
a number of significant technical improvements relevant to improving
data quality and preserving safety have been implemented. These
include improved technology and strategies for generating sterile
hyperpolarized material using a commercial device, the SPINlab, new
MR data acquisition sequences, and multichannel 1H/13C radio
frequency RF coils. Pictured in Figure 2 is the workflow for the
current-generation SPINlab which is now used routinely in patient
studies and provides automated polarization, dissolution, and quality
assurance system. The SPINlab polarizer uses a 5-T magnetic field
and operates at ~0.8 K. It has the capacity to polarize up to four
samples simultaneously, thus opening the door for the injection of
multiple HP probes within a single imaging exam. A critical part of
the SPINlab polarization and quality assurance process is the fluid
path that enables polarization in a closed system to minimize the
potential for microbial contamination. Compared to the initial
human study using a prototype polarizer in a clean room, the
achievable polarization of [1-13C]pyruvate has more than doubled
(from ≈18% to ≈40%), and the time to delivery of HP 13C pyruvate
was reduced (from ≈68 seconds to ≈55 seconds). Around the world,
seven sites have performed human exams using the SPINlab polarizer,
and more than 20 have been installed.
While initial patient studies have focused on [1-13C]pyruvate,
[2-13C]pyruvate has recently been FDA approved and is being added
Table 1. Current Hyperpolarized 13C MRI Clinical Trials—ClinicalTrials.gov
Hyperpolarised 13C-Pyruvate MRI Study Cancer
Cardiovascular diseases
University College London, London, UK
Effect of Cardiotoxic Anticancer Chemotherapy on the
Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria
Breast neoplasms UT Southwestern–Advanced Imaging
Research Center, Dallas, TX, USA
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic
Imaging in Predicting Treatment Response in Participants With Prostate Cancer
Prostate adenocarcinoma
PSA level greater than 10
Stage IIB prostate cancer AJCC v8
(and 7 more...)
M D Anderson Cancer Center, Houston,
TX, USA
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance
Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With
Central Nervous System Tumors
Malignant central nervous system neoplasm
Metastatic malignant neoplasm in the central nervous system
Stanford University School of Medicine
Palo Alto, CA, USA
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13
Pyruvate
Traumatic brain injury UT Southwestern–Advanced Imaging
Research Center
Dallas, TX, USA
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway Fatty liver
Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial
Metastasis Treated With (SRS)
Brain metastases Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical
Cancer (LACC) Cervical Cancer
Uterine cervical neoplasms Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients
Receiving Neoadjuvant Chemotherapy
Breast cancer Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic
Resonance Spectroscopic Imaging (MRSI)
Brain tumor adult
UTSW HP [13-C] Pyruvate Injection in HCM Cardiomyopathy, hypertrophic UT Southwestern Medical Center - Advanced
Imaging Research Center
Dallas, TX, USA
Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in
Children With Brain Tumors
Pediatric brain tumors UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco, CA, USA
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor
Malignancies
Prostate cancer University of California, San Francisco
San Francisco, CA, USA
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in
Castration-Resistant Prostate Cancer
Prostate cancer University of California, San Francisco
San Francisco, CA, USA
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer Prostate cancer Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection Hypertension
Hypertrophy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Multiparametric MRI for Prostate Cancer Localization and Characterization Using
Hyperpolarized Pyruvate (13C) Injection
Prostatic neoplasms Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate
Cancer
Prostate cancer University of California, San Francisco
San Francisco, CA, USA
MRI With C13 Pilot Study Prostate Cancer Prostate cancer University of California, San Francisco
San Francisco, CA, USA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility Malignant solid tumors Memorial Sloan Kettering Cancer Center
New York, NY, USA
Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer Prostate cancer University of California San Francisco
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clinical research studies are working toward the use of 13C urea,
[5-13C]glutamine, [1-13C]alpha-ketoglutarate, and [1,4-13C2]fuma-
rate in patient studies. To aid with submitting investigator-initiated
Investigational New Drug (IND) applications for future patient
studies, the IND for the use of [1-13C]pyruvate was transferred to the
NCI and is available on the following website (https://imaging.cancer.
gov/programs_resources/cancer-tracer-synthesis-resources/
hyperpolarized-C13-pyruvate-documentation.htm).
Early Patient Validation Studies
Early patient validation studies involving test-retest reproducibility,
correlations with pathologic findings, and clinical outcomes such as
survival and disease progression after treatment have been initiated
(data available from clinicaltrials.gov). In a study utilizing 2D
dynamic EPSI of preprostatectomy prostate cancer patients
(NCT02421380), time to max pyruvate was reproducible when
corrected for the arterial input function with no significant difference
observed in repeat injections of the same patient within the same
exam.106 In two recent clinical trials of prostate cancer patients
preprostatectomy (NCT02526360) and before and after treatment
(NCT02911467), a 3D dynamic compressed sensing EPSI sequencewas used to obtain full prostate coverage and to model the apparent
rate of pyruvate to lactate conversion, kPL. In the setting of advanced
prostate cancer, early (6 weeks) after effective androgen deprivation
therapy, there was a significant early reduction in kPL that receded
changes in mp-1HMRI and predicted clinical response (Figure 3).107
Comparison with current state-of-the-art imaging modalities such as
1H MRI is key to determining the added value of HP 13C MRI, and
with current HP 13C MRI studies expanding to metastatic sites
within the body,108,109 the synergy of HP MRI with currently used
PET probes will also need to be investigated.
There are currently a number of single-institution HP 13C MRI
clinical trials in the setting of breast, cervical, liver, and brain cancer,
and an initial multisite clinical trial for prostate cancer (Table 1).
Following promising preclinical studies in brain tumors, multiple
sclerosis, and traumatic brain injury, the feasibility of using HP 13C
MRI for evaluating brain metabolism in patient studies was recently
demonstrated.110,111 These studies demonstrated that [1-13C]
pyruvate are transported across the blood brain barrier and that
conversion to [1-13C]lactate can be detected in regions of both tumor
and normal brain. Interestingly, the rate of conversion in normal
brain was substantially higher than had previously been observed in
anesthetized preclinical models. For dynamic slab-localized and 2-D
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it was also possible to observe the conversion of HP pyruvate to
bicarbonate, which may discriminate between tumor and normal
brain. Additional studies are needed to optimize the pulse sequences,
RF coils, and experimental design to observe all three resonances at a
finer resolution and with volumetric coverage. Single-institution
studies that have been funded by the NIH include protocols for
obtaining data from the normal brain, in primary brain tumors prior
to image-guided surgery, and for comparing that conversion to
[1-13C]lactate/[1-13C]pyruvate in patients pre- and posttreatment
with radiation and temozolomide.
There are also several clinical trials investigating noncancerous
diseases, such as cardiomyopathy, hypertrophy and hypertension, and
fatty liver disease (Table 1). Altered cardiac energetics is known to play
an important role in the progression toward heart failure, and a recent
study demonstrated the feasibility of assessing pyruvate metabolism in
vivo in humans.97 The appearance of 13C-bicarbonate signal after
administration of hyperpolarized [1-13C]pyruvate was readily detected
in a cohort of healthy controls, suggesting that this technology may 1
day allow a direct measure of flux through the PDC in the in vivo
human myocardium, providing a means for understanding therapeutic
approaches that target metabolism.
While prior and ongoing HP 13C MRI patient studies have
addressed many of the initial obstacles, there remain a number of
challenges to the robust clinical translation of hyperpolarized [1-13C]
pyruvate MRI and its full FDA approval, as well as the translation of
other new hyperpolarized probes into the clinic. These challenges are
discussed in the following section.Challenges in Translation to Clinical Research and
Practice
Compared to current metabolic imaging methods based on positron
tomography, HP 13C MRI technology offers superior information
yield about fluxes in metabolic pathways without the constraints of
ionizing radiation. Nevertheless, while other potential benefits such as
safety and patient acceptability may be substantial, the central
question for clinical translation is whether HP 13C MRI provides
actionable clinical information that is inaccessible by other methods.
In examining how this question can be answered in the affirmative,
we can take some cues from the use of FDG PET/CT.112,113
The Clinical Role of Imaging in Cancer
The traditional clinical roles for imaging in cancer are detection,
diagnosis, staging, and monitoring therapy.114 More specifically,
imaging techniques are typically used in the clinic to detect the
tumor through screening; to guide cancer diagnosis, including tissue
sampling; and to determine the extent of cancer spread. More recently,
molecular imaging in particular has been used as a cancer biomarker to
help direct treatment.115,116 Already demonstrated in animal models20
and initial patient studies,107 this capacity to rapidly detect response to
treatment is perhaps the most promising in terms of clinical translation.
Because a response to therapy prior to any change in tumor volume
could occur within days, or even hours, the ability to detect this change
could redirect therapy to improve therapeutic efficacy and avoid
unnecessary toxicity for ineffective treatments, potentially saving lives
and alleviating suffering.
The complexity, expense, and requirement for administering an
imaging agent will likely limit HP MRI's role as a primary screening
tool. However, coupled to blood or urine metabolic biomarkersindicative of cancer risk and specific cancer metabolic signatures,117
HP MRI could provide a very powerful, targeted detection tool in
stratified populations. It could play a key role in diagnosis, for
example, as metabolic features identified by HP MRI might provide a
both sensitive and specific means of identifying cancer and clarifying the
benign ormalignant nature of findings seen on anatomic imaging—as is
the case in the application of FDG PET to pulmonary nodules detected
by CT.118 Since HP MRI is readily coupled to the anatomic
information acquired from standard MRI, it may also be particularly
helpful in directing tissue sampling by identifying the sites most
suspicious for cancer or, in the case of large cancer or widespread lesions,
indicating the lesions that appear most aggressive. Finally, HP MRI
could play a role in stratifying tumors identified by other imaging
modalities. Also, the application of HP MRI for systemic staging is
unlikely in the short term as it would require a whole-body capability
similar to that of PET/CT, the development of which would have to
overcome several technical challenges. However, as discussed above,
these technical challenges are beginning to be addressed in ongoing
phase II clinical trials of metastatic cancer.
Our understanding of cancer metabolism is primarily based on cell
and murine models whose relevance to human malignancies is
unclear. Consequently, in addition to the traditional roles of
imaging in cancer management, HP MRI could provide clinical
value based on its capacity to identify specific therapeutic targets in
vivo in humans, i.e., serve as companion diagnostics. Accordingly,
the presence of accelerated lactate production could direct the use of
LDH inhibitors, while altered mitochondrial metabolism might
suggest therapeutic options to renormalize metabolic activity.
How Could HP Information Change a Therapeutic Decision?
Since the publication of the first white paper,3 a number of reports
have appeared on the evaluation of cancer biomarkers and cancer
imaging methods.114,117,119–122 HP 13C MRI holds great promise as
an imaging biomarker of cancer. An imaging biomarker has been
defined as an anatomic, biochemical, or molecular parameter
detectable with an imaging method that is useful for establishing
the presence or severity of disease.123,124 As we have already
mentioned, metabolic alteration is an important phenotypic feature
of cancer that predicts disease behavior and can itself be a therapeutic
target.121,125 A critical consideration in the translation of a new
biomarker into the clinic is the impact of the test necessary for
obtaining this biomarker on clinical practice and patient outcome.119
In other words, does the test lead to better, more effective, and/or
more cost-effective patient treatment? As a cancer molecular imaging
biomarker, HP 13C MRI has the potential to address the following
five clinical needs.115
First, HP MRI could prove beneficial by detecting disease prior to
its initial clinical manifestation—in high-risk patients, for example—
or as a secondary diagnostic test, indicating the likelihood that
abnormal findings from screening or staging studies represent a
malignancy. It could also prove valuable by helping to stratify disease
severity after a diagnosis. Second, HP MRI could identify specific
sites for tissue biopsy for cancer diagnosis and characterization. A
third important benefit would be the capacity to predict disease
progression based on evidence of metabolic hyperactivity or the
integrity of metabolic pathways that enable metastasis. Fourth, HP
MRI may provide an early, pharmacodynamic measure of drug
efficacy, which could in turn predict the likelihood of therapeutic
futility, by measuring the impact of a given drug on regional cancer
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contribution, as it would enable the avoidance of ineffective
chemotherapy with the attendant morbidity and expense. Finally,
HP MRI could prove useful in evaluating prognosis and indicating
overall response—using the eradication of aberrant metabolism as a
highly predictive indicator of disease resolution, akin to the use of
FDG PET/CT in lymphoma.126 In this context, the role of HP
would be to determine whether or not treatment has eliminated the
cancer, as well as to help determine if there is a need for additional
treatment by predicting the likelihood of disease relapse or
progression. In summary, biomarker applications are likely to
represent the most compelling use of HP 13C MRI in relation to
cancer since its unique ability to characterize and quantify cancer
metabolism provides a means for inferring the impact of targeted
therapeutic interventions.122,127
What Will a Clinician Look for in Studies of HP Validation?
Experience with cancer diagnostics119,120 suggests that the general
term “validation”may refer to distinct criteria: validity with respect to
analytical results, validity for the purpose of a clinical diagnosis, and
validity for the purpose of modifying patient care, which could also be
termed clinical utility. In order to support the use of HP 13C MRI in
clinical trials and clinical practice, investigations relevant to all three
classes of data will be needed.
Analytic validity will be an important question, as clinicians will
need to understand what HP 13C MRI is measuring and see evidence
that these measurements are accurate. One approach to establishing
the analytic validity of HP MRI is to compare its results with those of
other PET-based tracer experiments. Demonstrating the reproduc-
ibility of hyperpolarized imaging exams is another important step and
will require establishing standardized and repeatable methods for HP
MR image acquisition and interpretation. Clinical validity, on the
other hand, refers to the capacity of a test to separate a given patient
population into two groups, such as those with and without a disease.
To establish their clinical validity, HP MRI results must be compared
to an accepted clinical standard such as the tissue or laboratory-based
assays with which oncologists are most comfortable. Another
important aspect of demonstrating HP MRI's clinical validity will
be its comparison to FDG and other PET imaging methods, and for
this reason, investment in facilities capable of performing both exams
is critical.
It is important to acknowledge, however, that establishing the
clinical validity of a given technology does not in and of itself
demonstrate that this technology should be used in patient care
decisions. Rather, that determination is ultimately based on clinical
utility, which refers to the technology's capacity to appropriately
direct patient care. In assessing the clinical utility of HP 13C MRI,
clinicians will look for validation against clinical outcomes, accuracy
(sensitivity, specificity, receiver operating characteristic area) versus a
reference standard in diagnostic applications, and predictive accuracy
in assessing therapeutic response. It will therefore be important to
know to what extent the data provided by HP MRI accurately
reclassify a patient, after all conventional studies are complete, into
the proper category—classified either as normal (with a normal HP
exam) or as disease (with an abnormal HP exam). Additional criteria
will include the risk or discomfort of the exam relative to the new
information it provides and, of course, the cost. Utility will be a key
component of later clinical trials, in which assessment of the impact
on patient outcomes and the cost of medical care provide data forcoverage decisions by payers, which is one of the most important
determinants of whether or not a new test is actually used in the
clinic.119
Comparison to Positron Tomography
Lessons learned from other quantitative molecular methods such as
PET can help guide the approach to quantitative image analysis using
HP MRI. For example, studies have shown that more sophisticated
quantitative methods such as compartmental kinetic analysis can
improve the ability to measure therapeutic response and predict
patient outcomes128; however, this improvement must be balanced
against the ability to implement more complex methods in the
clinic.129 Experience suggests that necessary simplification is best
achieved by collecting detailed data in early studies and then testing
the impact of simplification against more rigorous analytic
approaches.130
Combining HP MRI and PET data in kinetic analysis may be
especially powerful in characterizing cancer metabolism, as the two
methods provide complementary information. Long half-life and
relatively straightforward image quantification make PET a robust
method for quantifying flux through certain specific biochemical
pathways, such as the flux of glucose through hexokinases as a
measure of glycolysis or of thymidine through TK as a measure of
cellular proliferation. However, since isotopic emissions are not
impacted by the chemical species to which the isotope is attached,
PET provides no information about the nature of the molecule
attached to the label. HP 13C MRI, on the other hand, provides
exquisite information on the evaluation of metabolites of the
injected substance—such as for lactate from pyruvate—while its
shorter half-life makes studies of metabolic trapping difficult. Taken
together, the two methods can provide comprehensive information
on metabolic fluxes, especially at major branch points in metabolic
pathways such as the conversation of pyruvate to lactate in
glycolysis.
Future Directions: Initial Studies and Clinical Study Design
Early Clinical Trials. Existing guidelines for designing and
reporting on clinical trials of biomarkers provide a helpful template
for HP 13C MRI.131 Early studies must refine and test robust
methods for image acquisition and analysis to provide a uniform (and
uniformly accepted) approach to be used in subsequent clinical trials.
Early studies should also include tests of repeatability/precision to
measure the qualitative and quantitative variability of HP imaging
results, typically using a test/retest paradigm.113 Guidelines based on
results from early clinical trials are important for subsequent trials and
eventual clinical use, as the NCI consensus guidelines on FDG PET/
CT have demonstrated.132 Finally, early clinical trials should validate
HP 13C MRI against an accepted reference standard for cancer
diagnosis and characterization, typically based on tissue sampling.
This reference standard can be the presence or absence of cancer for
diagnostic applications, or specific assays that might serve as a
reference for imaging measures and which are often established in
preclinical studies. In addition to standardizing imaging approaches,
reporting of adverse events also could be standardized to facilitate
regulatory approval down the road.
The latter phase of imaging trials for biomarker applications should
evaluate new imaging tests for their accuracy in predicting important
clinical cancer outcomes such as therapeutic response, progression--
free survival, and overall survival. Early studies must establish the
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novel imaging is embedded in a clinical trial but is collected in a
purely observational fashion for comparison against clinical outcomes
measured in the treatment trial.133 Once validated in integral
biomarker trials, the imaging marker can be used to direct therapy in a
clinical trial and, later, in clinical practice. An example can again be
found in the application of FDG PET/CT to lymphoma, where the
resolution of abnormal FDG uptake, known as a complete metabolic
response, was shown to be highly predictive of disease-free survival
and is now used as an integral marker in clinical trials and for clinical
practice.126
Multisite Trials. Multisite clinical trials will be expected prior to
FDA approval of [1-13C]pyruvate as an imaging agent, and certain
specific obstacles will have to be addressed in designing them. In
addition to requiring novel imaging hardware, acquisition methods,
and analysis, HP 13C MRI carries the added challenge of requiring
the administration of a short-lived, locally produced imaging probe,
the production of which requires onsite personnel with expertise in
producing HP agents, monitoring their quality, and assuring patient
safety and regulatory compliance. The ability to produce uniformly
high-quality HP imaging agents across multiple centers is therefore a
crucial step in moving to multicenter clinical trials and eventual
clinical practice. Once again, some lessons can be learned from recent
multisite tests of investigational PET probes, which share many of
these requirements.134,135 The foremost requirement is that of
validated, uniform standards for probe production that will support
equivalent probe quality across all sites involved participating in
multicenter trials. This allows operation under a common regulatory
framework—for example, an NCI-held IND136 for multicenter
clinical trials—and assures patient safety and consistency of the drug
product. Standardized, robust image acquisition methods are also
needed, as are methods for testing and qualifying equipment and
personnel involved in HPMRI studies to ensure high-quality imaging
data at all participating sites.
Experience suggests a multistep approach leading to multicenter
trials for novel imaging approaches such as MRI of HP [1-13C]
pyruvate119 will be key for obtaining full FDA approval. Early studies
to test the potential accuracy and utility of new imaging methods are
often best done in single-center studies at expert institutions invested
in the technology. Early multicenter phase II trials should be small
enough to assure the ability of sites to acquire the imaging data in a
uniform and reproducible fashion and should validate the findings
from single-center trials; indications supported by small multicenter
trials can then be carried into larger phase III studies using
well-defined, prospective procedures for image analysis, with study
design and sample size calculations guided by results from smaller
multisite or single-site trials. Larger phase II trials should include
endpoints for safety and efficacy—in this case defined as diagnostic
accuracy. These larger studies should also gather information on
therapeutic impact and cost-effectiveness, key data for coverage
decisions by the Center for Medicare and Medicaid Services and other
payers.
Education, Training, and Certification
In addition to regulatory approval, translation to clinical practice
will require training for staff members who produce HP probes and
carry out HP 13C MR imaging. Imaging physicians will also need to
be trained in this new imaging modality: not only how to interpret the
data it provides but also how to safely and effectively administer HPimaging probes. Experience with other highly specialized imaging
methods such as PET and breastMRI137,138 suggests that requirements
for physician training and certification will be important in assuring
uniform diagnostic quality across all sites of practice. Finally, even after
clinical practice implementation, ongoing clinical research will be
critical for sustaining and optimizing clinical use.
Recommendations for Future Research
Since the publication of the first NIH white paper on hyperpolarized
13C MRI in 2011, numerous preclinical studies have demonstrated
this technology's unique metabolic imaging capabilities in the context
of cancer. There have now been over 200 HP 13C MRI human
studies performed to date worldwide at 7 different medical centers,
and over 5 more sites plan to initiate patient studies within the next 6
months. All of these studies have shown that HP 13C pyruvate MRI is
safe and also effective in detecting key metabolic conversions in
patients with a variety of diseases and even in normal volunteers. It is
important to recognize that demonstrating the clinical safety and
feasibility of HP MRI technology is not enough to ensure its
widespread clinical implementation. If the latter is to be achieved, it
will be because future trials are able to successfully establish its clinical
utility. In addition, widespread clinical implementation also implies
regulatory approval and reimbursement approvals around the world.
Commercialization of HP [1-13C]pyruvate MRI will require a
comprehensive regulatory and sponsorship strategy that will also
depend on the potential clinical utility. We have developed a number
of recommendations with this ultimate goal in mind.
First, it is necessary to continue refining the protocols, new HP
agents, and investigative targets of ongoing preclinical studies in a
translational direction with refined pharmacy methods for reliable,
lower-cost production of sterile HP solutions. Also, it is valuable to
verify that metabolic measurements in animal models of cancer and
other disease states correspond to those performed in human disease,
and to incorporate these measurements into disease hypothesis testing
and development of new hyperpolarized agents. Improved quantita-
tive analysis of metabolite signals and enzymatic rate kinetics obtained
from HP [1-13C] pyruvate will be a critical aspect of this. It is also
imperative to identify the metabolic network(s) associated with the
metabolism of specific hyperpolarized agents in order to select the
appropriate agent for the study of specific disease conditions and
therapies, and to appropriately guard against incorrectly associating
apparent metabolic changes with the wrong cause. Additionally, there
is a need for more studies which focus on determining the origins of
variability in therapeutic response through separate HP measures of
uptake and metabolism, and to use these HP probes to identify and
better understand therapeutic response and nonresponders at earlier
time points.
Further efforts to develop improved imaging pulse sequences and
RF coils for imaging different organs, agents, and disease states will be
critical for increased quality, information content, and applicability.
New RF hardware should enable body-coil transmit and multichan-
nel (32 at least) reception for all parts of the body with both 13C and
1H frequency excitation and reception. Analysis methods for the
reliable calculation of enzymatic rate constants, such as kPL for the
LDH catalyzed conversion of pyruvate to lactate and kPB for pyruvate
to bicarbonate, need to be refined and tested in patient and volunteer
studies at multiple sites. In the context of cancer more specifically,
another vital avenue for future studies will be the development of new
HP agents capable of probing the ancillary and often-unexpected
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therapy. Specialized MR pulse sequences for the new agents will be
required and 1H detected-13C spectroscopy techniques should be
developed and investigated for increased sensitivity with the added
advantage that spatial information can be encoded at the 1H
frequency.
There are also a number of needs to be addressed at an institutional
level. First and foremost, the mechanism(s) for multisite clinical trials
must be established—both through the identification of sites that
possess the necessary equipment and by developing the appropriate
investigative protocols. In order to support these efforts, it is
important to promote the development of pedagogical resources for
real-time metabolic imaging, perhaps through the establishment of
new pre- and postdoctoral training programs focused on developing
relevant techniques.
Finally, widespread clinical translation will not be possible without
the continued development of robust collaborations among basic
science investigators, clinical oncologists, and those with expertise in
clinical study design. This collaborative work must be bolstered by
strong partnerships between academia, funding agencies, and
industry.
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